Big Pharma backs $100M dementia R&D fund

Some of the top companies in Big Pharma have contributed to a $100 million venture fund that will be invested in R&D aimed at finding new therapies for Alzheimer's. Biogen ($BIIB), GlaxoSmithKline ($GSK), Johnson & Johnson ($JNJ), Lilly ($LLY), Pfizer ($PFE) and Takeda joined hands with the U.K. government in coming up with the cash for the Dementia Discovery Fund, which will be managed by SV Life Sciences. The game plan at the new fund will be to invest in preclinical research activities. Alzheimer's afflicts millions of people around the world, but the late-stage pipeline has been afflicted by repeated failures as researchers continue to puzzle out what triggers the memory-stealing disease. Release

Suggested Articles

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.

After spinning out two companies at the start of the year, Sosei Heptares has now inked a new deal with Roche biologics unit Genentech.